Revance therapeutics, inc. (RVNC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-159,400

-142,568

-120,587

-89,300

-73,476

-62,917

-52,448

-58,259

Adjustments to reconcile net loss to net cash used in operating activities:
Interest on convertible notes converted to convertible preferred stock

-

-

-

-

-

-

9,220

18,830

Interest for 2013 Notes and Essex Notes upon issuance, non-cash

-

-

-

-

-

271

273

0

Capitalized interest

-

-

-

-

0

972

453

0

Fair value of common stock warrants issued

-

-

-

-

-

379

0

0

Effective interest on financing obligations

-

-

-

-

344

28

0

0

Gain on disposal of property and equipment

8

1,466

0

0

-

0

0

-

Asset Impairment Charges

0

0

2,927

9,100

0

0

-

-

Non-cash in-process research and development

-

-

-

2,000

0

0

-

-

Amortization of discount on debt and capital leases

-

-

-

-

-

1,250

4,128

7,427

Amortization of debt issuance cost

-

-

-

-

-

203

217

300

Change in fair value of derivative liabilities associated with convertible notes

-

-

-

-

-

4,032

2,660

13,860

Change in fair value of derivative liability associated with Medicis settlement

-

-

-

-

127

-320

47

0

Change in fair value of common stock warrant liability

-

-

-

-

-

2,151

621

0

Change in fair value of convertible preferred stock warrant liability

-

-

-

-

-

210

-425

125

Extinguishment of warrant liability upon exercise of put option

-

-

-

-

-

1,356

0

0

Convertible preferred stock warrant modification remeasurement adjustment

-

-

-

-

-

-

1,168

0

Loss on extinguishment of 2013 Notes

-

-

-

-

-

-8,331

0

0

Stock-based compensation

17,922

16,273

13,230

11,953

12,388

6,530

548

79

Depreciation

2,909

1,726

1,468

1,445

1,995

2,051

1,900

1,777

Amortization of discount on investments

2,637

1,103

-410

-1,212

-601

0

0

-

Other non-cash operating activities

810

175

767

1,013

82

-

-

-

Issuance of common stock for service rendered

-

-

-

-

-

-

-

3,225

Derivative liabilities recognized as result of Medicis settlement agreement

-

-

-

-

-

-

-

15,268

Changes in operating assets and liabilities:
Accounts receivable

-27,000

26,952

-80

-30

-

-

-

-

Prepaid expenses and other current assets

1,377

2,911

-4,849

5,621

192

999

-422

1,125

Operating lease right of use assets

1,868

0

0

-

-

-

-

-

Other non-current assets

-1,578

1,871

403

151

-29

1,621

2,770

-257

Accounts payable

-360

1,691

2,607

953

-692

-3,399

3,193

1,028

Accruals and other liabilities

3,565

1,488

-690

7,502

3,179

2,311

-3,832

2,976

Deferred revenue

4,587

51,272

0

0

-

-

-

-10,500

Operating lease liabilities

1,147

0

0

-

-

-

-

-

Deferred rent

-

-

-

48

-200

-549

-133

-238

Payments against Medicis liabilities

-

-

-

-

-

-7,073

-6,927

0

Net cash used in operating activities

-106,161

-104,246

-95,342

-59,827

-55,669

-55,073

-47,758

-38,914

CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments

331,362

314,911

36,028

280,681

54,087

0

0

-

Purchases of property and equipment

3,238

6,991

2,525

1,670

3,328

6,975

6,477

319

Proceeds from maturities of investments

317,000

146,000

157,445

207,650

1,000

0

0

-

Purchases of property and equipment

8

1,541

0

2

0

0

-

-

Proceeds from sale of investments

0

67,435

0

1,000

0

0

-

-

Proceeds from sale of property and equipment

0

100

100

1,800

0

0

-

-

Change in restricted cash

-

-

-

-

-

-

-75

-75

CASH FLOWS FROM FINANCING ACTIVITIES

-17,592

-107,026

118,792

-75,499

-56,415

-6,975

-6,402

-244

Proceeds from issuance of common stock in connection with offerings, net of commissions and discount
Payments to settle warrants

-

-

-

-

-

1,438

0

0

Payment of offering costs

742

366

644

243

0

0

-

-

Proceeds from issuance of common stock, net of deferred initial public offering costs

-

-

-

-

-

102,672

-

0

Proceeds from issuance of convertible notes and notes payable

-

-

-

-

-

6,750

21,903

18,170

Proceeds from issuance of common stock in connection with offerings, net of commissions and discount

211,970

0

157,468

0

0

-

-

-

Proceeds from Issuance of Common Stock

10,870

0

38,760

0

10,021

0

-

0

Proceeds from issuance of common stock in connection with the 2015 follow-on offering, net of deferred offering costs

-

-

-

-

126,230

131,880

-

-

Proceeds from the exercise of stock options and common stock warrants

937

5,292

4,569

1,649

2,753

1,771

18

6

Net settlement of restricted stock awards for employee taxes

1,378

2,212

573

507

993

0

0

-

Principal payments made on financing obligations

0

932

3,636

3,541

2,598

228

982

1,154

Principal payments made on notes payable

-

-

-

-

2,652

12,316

7,594

3,403

Proceeds from failed sale-leaseback financings

-

-

-

-

9,831

0

0

-

Proceeds from the exercise of common stock warrants

-

-

-

-

-

-

-

1

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

-

40,646

0

Net cash provided by financing activities

221,657

1,782

195,944

-2,642

142,592

229,091

53,991

13,620

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH

97,904

-209,490

219,394

-137,968

30,508

167,043

-169

-25,538

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Issuance of convertible preferred stock warrants

-

-

-

-

-

80

139

0

Fair value of common stock warrants issued

-

-

-

-

-

379

0

0

Accrued transaction costs on convertible senior notes

293

354

251

134

-

-

-

-

Cash paid for income taxes

3,000

0

0

-

-

-

-

-

Cash paid for interest

0

16

299

676

802

1,182

1,590

2,302

SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:
Conversion of Series E-1, E-2, E-3, E-4 and E-5 preferred stock into common stock

-

-

-

-

-

123,982

0

0

Conversion of 2013 Notes into common stock

-

-

-

-

-

26,206

0

0

Issuance of common stock upon net exercise of common stock warrants in connection with IPO

-

-

-

-

-

6,490

0

0

Fair value in excess of debt host for derivative liabilities associated with convertible notes

-

-

-

-

-

1,050

5,750

2,255

Deferred initial public offering costs

-

-

-

-

-

4,028

2,490

0

Deferred follow-on public offering costs

-

-

-

-

0

546

0

0

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

-

1,441

0

0

Conversion of Essex Notes into financing obligations

-

-

-

-

-

1,095

0

0

Termination of stock option repurchase right

-

-

-

-

-

58

0

0

Capital contribution on the extinguishment of the prior convertible preferred stock

-

-

-

-

-

-

74,894

0

Capital contribution on the extinguishment of the 2011 Notes

-

-

-

-

-

-

32,008

0

Deemed dividend on issuance of Series E-5 convertible preferred stock

-

-

-

-

-

-

177

0

Issuance of common stock warrants in connection with Series E-5 convertible preferred stock financing

-

-

-

-

-

-

4,272

153

Issuance of common stock warrants in connection with the 2013 Notes

-

-

-

-

-

981

2,737

0

Property and equipment purchases included in accounts payable and accruals

619

642

718

200

487

1,348

2,285

0

Holdback related to acquisition of in-process research and development

-

-

-

200

0

0

-

-